(a) Define poison and classify it. Describe the treatment of venomous snakebite. Write a note on 'designer drug'. 15 marks (b)…

(a) Poison, Snakebite Management, and Designer Drugs

A poison is any substance (solid, liquid, or gas) which, when administered, inhaled, or absorbed into a living organism, causes sickness, structural damage, or death through its local or systemic chemical action.

Poisons are classified based on origin into animal (venoms, cantharides), vegetable (strychnine, opium, ricin), and mineral/synthetic (arsenic, lead, organophosphates); based on target organ into neurotoxic, cardiotoxic, nephrotoxic, and hepatotoxic; and clinically/forensically into corrosives (strong acids/alkalis), irritants (metallic, mechanical), and systemic poisons (cerebral, spinal, peripheral, cardiac).

Treatment of Venomous Snakebite: In India, most envenomations are caused by the "Big Four" (Russell’s viper, Saw-scaled viper, Common krait, Spectacled cobra). Management comprises:

1. First Aid: Reassure the patient, immobilize the affected limb with a splint at heart level, and avoid incisions, suction, or arterial tourniquets. Pressure immobilization is reserved for neurotoxic elapids.
2. Antivenom Therapy: Lyophilized polyvalent Anti-Snake Venom (ASV) is the definitive antidote, administered via intravenous infusion (10 vials initially) guided by the 20-minute Whole Blood Clotting Test (20WBCT) for vipers or neuroparalytic signs for elapids.
3. Complications and Adjuncts: Immediate anaphylaxis is managed with intramuscular adrenaline (0.5 mg, 1:1000) and hydrocortisone. Delayed serum sickness is treated with oral corticosteroids. Neurotoxicity responds to neostigmine with atropine and mechanical ventilation; acute kidney injury secondary to hemotoxicity requires hemodialysis.

Designer Drugs: These are synthetic structural or functional analogues of controlled psychoactive substances synthesized to circumvent drug enforcement legislation. Major classes include synthetic cannabinoids (Spice, K2), synthetic cathinones ("bath salts", mephedrone), and synthetic opioids (fentanyl analogues). In India, extensive seizures by the Narcotics Control Bureau (NCB) of mephedrone ("meow-meow") under the NDPS Act highlight their rapid emergence, high addiction liability, and fatal toxicity.

(b)(i) Oral Cancer: Predisposing Conditions, Pathogenesis, and Morphology

Predisposing factors include chronic consumption of tobacco (khaini, gutkha), betel quid with areca nut causing oral submucous fibrosis (OSMF), chronic alcohol consumption, high-risk Human Papillomavirus (HPV-16, HPV-18), Plummer-Vinson syndrome, and chronic mechanical irritation from jagged teeth.

Pathogenesis and Molecular Basis: Follows the multistep model of field cancerization, wherein carcinogen exposure produces widespread genetic alterations across the aerodigestive mucosa. Key molecular drivers include inactivation of tumor suppressor genes (TP53, CDKN2A/p16), amplification of EGFR and CCND1 (Cyclin D1), and activation of the PI3K/AKT/mTOR signaling pathway, driving progression from hyperplasia and dysplasia to invasive carcinoma.

Morphology: Macroscopically, lesions present as exophytic/fungating masses, endophytic ulcerations with indurated borders, or diffuse leukoplakic/erythroplakic plaques. Microscopically, the predominant type is Squamous Cell Carcinoma (SCC) and its variant, verrucous carcinoma. SCC shows nests and cords of malignant squamous cells displaying pleomorphism, mitotic figures, intercellular bridges, and concentric keratin pearls, graded into well, moderately, and poorly differentiated forms.

(b)(ii) Glomerular Responses to Injury and Pathogenesis of Glomerulonephritis

The glomerulus exhibits four primary pathologic responses:

1. Hypercellularity: Proliferation of mesangial or endothelial cells, parietal epithelial cell proliferation forming "crescents", and leukocytic infiltration.
2. Basement Membrane Thickening: Deposition of immune complexes (subepithelial, subendothelial, or intramembranous) or increased matrix synthesis (diabetic glomerulosclerosis).
3. Hyalinization: Extracellular accumulation of eosinophilic, amorphous plasma-protein-derived material.
4. Sclerosis: Accumulation of extracellular collagenous scar tissue obliterating capillary loops.

Pathogenesis: Immune-mediated injury is the primary driver. It occurs via:

1. In situ immune complex deposition: Antibodies directed against endogenous glomerular antigens, such as anti-GBM antibodies in Goodpasture syndrome or anti-PLA2R antibodies in primary membranous nephropathy.
2. Circulating immune complex entrapment: Subendothelial/subepithelial trapping of antigen-antibody complexes (post-streptococcal GN, lupus nephritis).
3. Cell-mediated and ANCA-associated injury: Pauci-immune mechanisms driven by anti-neutrophil cytoplasmic antibodies (granulomatosis with polyangiitis). These immune triggers recruit complement cascades (C3a, C5a, C5b-9 membrane attack complex), releasing chemotactic factors, reactive oxygen species, and cytokines (TGF-beta, TNF-alpha) that mediate glomerular destruction.

(c)(i) Mechanisms of Antimicrobial Resistance

Antimicrobial resistance (AMR) operates through several biochemical and genetic mechanisms:

1. Enzymatic Inactivation: Production of beta-lactamases, Extended-Spectrum Beta-Lactamases (ESBLs), and carbapenemases (e.g., New Delhi metallo-beta-lactamase-1, NDM-1), which hydrolyze the beta-lactam ring.
2. Target Modification: Structural alteration of drug binding sites, such as PBP2a production in Methicillin-Resistant Staphylococcus aureus (MRSA encoded by mecA), D-Ala-D-Lac cell-wall remodeling in Vancomycin-Resistant Enterococci (VRE via vanA), and topoisomerase/gyrase mutations in fluoroquinolone resistance.
3. Reduced Permeability: Downregulation or loss of outer membrane porins (e.g., OprD loss in Pseudomonas aeruginosa).
4. Active Efflux Pumps: Upregulation of energy-dependent multidrug efflux systems (e.g., AcrAB-TolC in Enterobacteriaceae).
5. Biofilm Formation: Production of an extracellular polymeric matrix preventing drug penetration.
6. Horizontal Gene Transfer: Dissemination of resistance determinants via conjugative plasmids, transposons, and integrons across bacterial populations.

(c)(ii) Third and Fourth Generation Cephalosporins

Third Generation: Parenteral agents include Ceftriaxone, Cefotaxime, Ceftazidime, and Cefoperazone; oral agents include Cefixime and Cefpodoxime proxetil. Fourth Generation: Cefepime and Cefpirome.

Therapeutic Indications:

1. Bacterial Meningitis: Ceftriaxone and Cefotaxime due to superior blood-brain barrier penetration.
2. Enteric/Typhoid Fever and Gonorrhea: Ceftriaxone as standard first-line therapy.
3. Pseudomonal and Nosocomial Infections: Ceftazidime, Cefoperazone, and Cefepime against Pseudomonas aeruginosa.
4. Febrile Neutropenia and Severe Sepsis: Cefepime and Cefpirome offer broad, balanced gram-positive and gram-negative coverage with resistance to common AmpC beta-lactamases.